1. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
- Author
-
Eldi P, Cooper TH, Prow NA, Liu L, Heinemann GK, Zhang VJ, Trinidad AD, Guzman-Genuino RM, Wulff P, Hobbs LM, Diener KR, and Hayball JD
- Subjects
- Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Humans, Immunity, Cellular, Immunity, Humoral, Mice, SARS-CoV-2, Spike Glycoprotein, Coronavirus genetics, Vaccination, COVID-19 prevention & control, Vaccinia
- Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens., (© 2022 The Authors. Immunology & Cell Biology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
- Published
- 2022
- Full Text
- View/download PDF